Key result
Escitalopram shows no benefit over placebo for depressive symptoms or clinical outcomes in heart failure.
Why the study?
Does escitalopram improve depressive symptoms or major clinical endpoints safely in patients with congestive heart failure?
Does escitalopram improve depressive symptoms or major clinical endpoints safely in patients with congestive heart failure?
Answers are grounded in this paper and cite their sources.
Escitalopram appears safe in patients with congestive heart failure, though it provides no additional benefit over placebo for improving depressive symptoms or major clinical endpoints.
No direct evidence for improved outcomes with escitalopram in CHF patients; its use appears safe but offers no additional benefit over placebo for depressive symptoms or major clinical endpoints.
No takes yet. Share an insight, caveat, or question.
Tripdatabase (2026) studied this question. Escitalopram appears safe in patients with congestive heart failure, but offers no additional benefit over placebo for depressive symptoms or major clinical endpoints.
Synapse has enriched 10 related papers. Consider them for comparative context: